secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2026-07-24T16:15:36+00:00
Accession:  0001140361-26-029541
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata Therapeutics terminates merger with Kuva Labs; Kuva failed to secure financing
--------------------------------------------------------------------------------

- Merger agreement terminated after Kuva Labs failed to obtain financing to fund tender offer.
- Kuva must pay Lisata a $2M termination fee under the agreement.
- Lisata reserves rights to seek damages for willful breach; no assurance of recovery.
- Board to assess strategic alternatives including reverse merger, business combination, asset sales, or dissolution.
- No timetable set for strategic review; no assurance of any transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000114036126029541/0001140361-26-029541-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000114036126029541/ef20078724_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-029541

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer